Editor, Scrip & Pink Sheet, covering pharmaceutical and business news and analysis; views expressed are purely my own.

Read Full Bio →


Eleanor has been Editor of Scrip Intelligence since 2014. She has worked on the title since 2000, reporting and analysing all aspects of the global pharma industry from M&A and partnering, financial and strategy news and trends through R&D to market access, policy and regulation. She has ...

Search Tweets

Twitter Feed

@ScripEleanor — 2,066 followers, 2,823 tweets

RT @Jessicaemerrill: They had taken some initiative to build out the pipeline last year to diversify beyond hemophilia. More business de…  https://twitter.com/i/web/status/955411840661643264 
$11.6bn - how much @sanofi is paying for @Bioverativ, hemophilia biz spun out of @biogen 1 year ago. Mkt cap then ~$5bn. Mkt cap now ~$7bn. $BVV $SNY
Interesting results for @DaVolterra charcoal product - an innovative approach to tackling the c-diff problem  https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jix604/4653556 
Show More